Cargando…
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
In June 2017, The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, organized a workshop entitled “Pharmacokinetics-Pharmacodynamics (PK/PD) for Development of Therapeutics against Bacterial Pathogens” to discuss details and critical parameters of vari...
Autores principales: | Rizk, M. L., Bhavnani, S. M., Drusano, G., Dane, A., Eakin, A. E., Guina, T., Jang, S. H., Tomayko, J. F., Wang, J., Zhuang, L., Lodise, T. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496063/ https://www.ncbi.nlm.nih.gov/pubmed/30833427 http://dx.doi.org/10.1128/AAC.02309-18 |
Ejemplares similares
-
Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013) -
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
por: Bulitta, Jürgen B., et al.
Publicado: (2019) -
Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
por: Leung, Elizabeth, et al.
Publicado: (2021) -
Considerations for the Use of Phage Therapy in Clinical Practice
por: Suh, Gina A., et al.
Publicado: (2022) -
Should the biofilm mode of life be taken into consideration for microbial biocontrol agents?
por: Pandin, Caroline, et al.
Publicado: (2017)